咨询与建议

限定检索结果

文献类型

  • 85 篇 期刊文献
  • 4 篇 会议
  • 1 册 图书

馆藏范围

  • 90 篇 电子文献
  • 0 种 纸本馆藏

日期分布

学科分类号

  • 63 篇 医学
    • 53 篇 临床医学
    • 15 篇 药学(可授医学、理...
    • 10 篇 基础医学(可授医学...
    • 6 篇 公共卫生与预防医...
    • 4 篇 中西医结合
  • 20 篇 理学
    • 12 篇 数学
    • 9 篇 统计学(可授理学、...
    • 4 篇 生物学
    • 3 篇 系统科学
    • 2 篇 化学
    • 1 篇 地理学
    • 1 篇 科学技术史(分学科...
  • 15 篇 工学
    • 7 篇 生物医学工程(可授...
    • 5 篇 计算机科学与技术...
    • 4 篇 软件工程
    • 2 篇 化学工程与技术
    • 2 篇 安全科学与工程
    • 1 篇 电子科学与技术(可...
    • 1 篇 水利工程
    • 1 篇 环境科学与工程(可...
    • 1 篇 食品科学与工程(可...
    • 1 篇 生物工程
  • 6 篇 管理学
    • 3 篇 管理科学与工程(可...
    • 2 篇 工商管理
    • 2 篇 图书情报与档案管...
  • 2 篇 经济学
    • 1 篇 理论经济学
    • 1 篇 应用经济学
  • 2 篇 法学
    • 1 篇 社会学
  • 1 篇 哲学
    • 1 篇 哲学
  • 1 篇 历史学
    • 1 篇 世界史
  • 1 篇 农学

主题

  • 5 篇 schizophrénie
  • 5 篇 palipéridone
  • 5 篇 thérapeutique
  • 5 篇 antipsychotiques
  • 2 篇 biomarkers
  • 2 篇 statistics
  • 2 篇 oncology
  • 1 篇 study duration
  • 1 篇 strong
  • 1 篇 weighted partial...
  • 1 篇 central subspace
  • 1 篇 mavorixafor
  • 1 篇 neutropenia
  • 1 篇 joint asymptotic...
  • 1 篇 spending functio...
  • 1 篇 survival
  • 1 篇 software package...
  • 1 篇 pain
  • 1 篇 linear rank test
  • 1 篇 kaplan-meier

机构

  • 7 篇 biostatistics & ...
  • 5 篇 emea maf janssen...
  • 5 篇 psychiatry hospi...
  • 5 篇 emea maf janssen...
  • 5 篇 emea medical aff...
  • 5 篇 biostatistics & ...
  • 4 篇 psychiatry and n...
  • 4 篇 psychiatry dicle...
  • 3 篇 biostatistics an...
  • 3 篇 biostatistics an...
  • 3 篇 emea medical aff...
  • 3 篇 clinica psichiat...
  • 3 篇 emea medical aff...
  • 3 篇 hospital clínic ...
  • 2 篇 biostatistics & ...
  • 2 篇 biostatistics an...
  • 2 篇 dicle university...
  • 2 篇 biostatistics an...
  • 2 篇 clinical develop...
  • 2 篇 chu de strasbour...

作者

  • 13 篇 schreiner a.
  • 13 篇 cherubin p.
  • 10 篇 bergmans p.
  • 9 篇 hargarter l.
  • 8 篇 parellada e.
  • 8 篇 carpiniello b.
  • 8 篇 vidailhet p.
  • 6 篇 rancans e.
  • 6 篇 bez y.
  • 3 篇 burmester gerd r
  • 3 篇 lin ji
  • 2 篇 hargater l.
  • 2 篇 c. roehrborn
  • 2 篇 j.j. grob
  • 2 篇 mertens c.
  • 2 篇 jayawardena shya...
  • 2 篇 m. campone
  • 2 篇 lévy-leduc célin...
  • 2 篇 zhang yiding
  • 2 篇 h. banerjee

语言

  • 86 篇 英文
  • 3 篇 其他
  • 1 篇 中文
检索条件"机构=Biostatistics and Programming"
90 条 记 录,以下是31-40 订阅
1098P Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial
收藏 引用
Annals of Oncology 2024年 35卷 S727-S728页
作者: R.J. Sullivan M. Lu S. Koppolu J.S. Weber M.S. Carlino M.A. Khattak G. Ansstas M.H. Taylor M. Mckean G.V. Long M.B. Faries J.J. Luke V. Sehgal A. Rao H. Mao J. Guo M. Brown R. Meehan I. Feldman L. Srinivasan Medical Oncology/Hematology MGH - Massachusetts General Hospital Boston MA USA Translational Medicine Moderna Inc. - Global Headquarters Cambridge MA USA Computational Science Moderna Inc. - Global Headquarters Cambridge MA USA Laura and Isaac Perlmutter Cancer Center NYU Langone Health New York NY USA Medical Oncology Melanoma Institute Australia and Westmead Hospital Sydney NSW Australia Oncology Hollywood Private Hospital and Edith Cowan University Perth WA Australia Oncology Washington University School of Medicine St. Louis MO USA Medical Oncology Earle A. Chiles Research Institute Portland OR USA Oncology Sarah Cannon Research Institute - Cancer Centre Nashville TN USA Melanoma Institute Australia The University of Sydney Royal North Shore and Mater Hospitals Sydney NSW Australia Surgical Oncology The Angeles Clinic and Research Institute a Cedars-Sinai affiliate Los Angeles CA USA Medicine - Hematology/Oncology UPMC Hillman Cancer Center and University of Pittsburgh Pittsburgh PA USA Biometrics Moderna Inc. - Global Headquarters Cambridge MA USA Clinical biomarkers Moderna Inc. - Global Headquarters Cambridge MA USA Biostatistics Moderna Inc. - Global Headquarters Cambridge MA USA Biostatistics & Programming Moderna Inc. - Global Headquarters Cambridge MA USA Clinical Development Moderna Inc. - Global Headquarters Cambridge MA USA Oncology Moderna Inc. - Global Headquarters Cambridge MA USA
来源: 评论
VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up
收藏 引用
Annals of Oncology 2022年 第9期33卷 986-987页
作者: S. Loibl J. Jassem A. Sonnenblick D. Parlier E. Winer J. Bergh R.D. Gelber E. Restuccia Y-H. Im C. Huang F. Dalenc I. Calvo M. Procter C. Caballero E. Clark H.L. Gomez Moreno J. Bliss G. Viale J. Bines M. Piccart Medicine and Research Dept. German Breast Group (GBG) Forschungs GmbH Neu-Isenburg Germany Oncology & Radiotherapy Medical University of Gdansk Gdansk Poland Oncology Department Tel Aviv Sourasky Medical Center-(Ichilov) Tel Aviv Israel Clinical Trials Support Unit Institut Jules Bordet Brussels Belgium Yale Cancer Center Yale University School of Medicine - Yale Cancer Center New Haven CT USA Department of Oncology-Pathology Karolinska Institutet and Breast Cancer Centre Cancer Theme Karolinska University Hospital Stockholm Sweden Biostatistics Dana Farber Cancer Institute Boston MA USA Product Development Oncology F. Hoffmann-La Roche Ltd Basel Switzerland Medicine Dept. Hematology/Medical Oncology Division Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine Seoul Republic of Korea Surgery Dept. NTUH - National Taiwan University Hospital Taipei Taiwan Oncologie 1A Institut Universitaire du Cancer Toulouse - Oncopole Toulouse France Breast Cancer Unit MD Anderson Cancer Center Madrid Madrid Spain Statistics and Programming Frontier Science Scotland Kincraig UK Medical Department Breast International Group (BIG) - AISBL Brussels Belgium Data Sciences - Data & Statistical Sciences (DSS) Roche Products Limited Welwyn Garden City UK Medicine Department INEN - Instituto Nacional de Enfermedades Neoplasicas Lima Peru Clinical Trials and Statistics Unit ICR - Institute of Cancer Research London UK Department of Oncology Università degli Studi di Milano Milan Italy Medical Oncology Department Instituto Nacional de Cancer - Research Center Rio de Janeiro Brazil Institut Jules Bordet Brussels Belgium
来源: 评论
9O Phase I/II, open-label, first-in-human study of the anti-GPC3 T cell engager SAR444200 in patients with advanced solid tumors: Updated safety and pharmacokinetic analysis
收藏 引用
ESMO Open 2025年 10卷 104165-104165页
作者: Almhanna, K. Hong, J.Y. Chenard-Poirier, M. Ryoo, B-Y. Lim, D.W-T. El-Khoueiry, A.B. Goh, B-C. Samol, J. Kefsi, A. Perez, R. Meng, R. Masciari, S. Abbadessa, G. Guillemin-Paveau, H. Lepine, L. Zhang, Y. Dumbrava, E.E. Medical Oncology Warren Alpert Medical School of Brown University Providence United States of America Hematology-Oncology Samsung Medical Center (SMC) Seoul Republic of Korea Gastrointestinal Cancer Unit Centre Intégré de Cancérologie - Chu de Québec Québec Canada Department of Oncology Asan Medical Center - University of Ulsan Seoul Republic of Korea Medical Oncology Department NCCS - National Cancer Centre Singapore Medical Oncology Division USC - Kenneth J. Norris Jr. Comprehensive Cancer Center Los Angeles United States of America Hematology-Oncology NCIS - National University Cancer Institute Singapore Singapore Medical Oncology Department National Healthcare Group - Tan Tock Seng Hospital Singapore Oncology Early Development Sanofi Vitry-sur-Seine France Immuno Modulatory Agents-Early Development Sanofi Bridgewater United States of America Research and Development Department Sanofi Cambridge United States of America Early Development in Oncology Sanofi Cambridge United States of America Oncology Early Development Sanofi Cambridge United States of America Pharmacokinetics/Pharmacodynamics VA Sanofi Vitry-sur-Seine France Pharmacokinetics Dynamics and Metabolism Sanofi Vitry-sur-Seine France Department of Biostatistics and Programming Sanofi Cambridge United States of America Investigational Cancer Therapeutics Department The University of Texas MD Anderson Cancer Center - Main Building Houston United States of America
来源: 评论
1411P Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
收藏 引用
Annals of Oncology 2023年 34卷 S807-S807页
作者: G.K. Dy B.C. Cho J. Oliveira M.D. Isla Casado A. Blasco Cordellat M. Zemanova J. Roubec L. Vila Martinez L. Charbonnier C. Soufflet J. de Castro Carpeño Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo NY USA Division of Medical Oncology Yonsei Cancer Center Yonsei University College of Medicine Seoul Republic of Korea Medical Oncology Service Early Phase Clinical Trial Unit-IPO Porto/RISE@CI-IPOP (Health Research Network Experimental Pathology and Therapeutics Group Research Center (CI-IPOP)/RISE@CI-IPOP (Health Research Network) Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Porto Portugal Medical Oncology Department Hospital Clínico Universitario Lozano Blesa Zaragoza Spain Medical Oncology Department Hospital General de Valencia Valencia Spain Department of Oncology First Faculty of Medicine Charles University and General University Hospital in Prague Prague Czech Republic Pneumooncology Nemocnice AGEL Ostrava-Vítkovice Ostrava-Vítkovice Czech Republic Oncology Department Consorci Corporació Sanitària Parc Taulí de Sabadell Sabadell Spain Biostatistics & Programming Sanofi Chilly-Mazarin France Clinical Development Sanofi Vitry-sur-Seine France Medical Oncology Service Hospital Universitario La Paz Madrid Spain
来源: 评论
P0054 - An integrated analysis of the efficacy of desvenlafaxine succinate compared with placebo in the treatment of major depressive disorder
收藏 引用
European Psychiatry 2020年 第S2期23卷 S208-S208页
作者: M.E. Thase S.G. Kornstein R. Tummala J.M. Germain Q. Jiang S. Ahmed P.T. Ninan Department of Psychiatry Mood and Anxiety Disorders Treatment and Research Program University of Pennsylvania Philadelphia PA USA Department of Psychiatry and Obstetrics and Gynecology Mood Disorders Institute and The Institute for Womens Health Virginia Commonwealth University School of Medicine Virginia Commonwealth University Richmond VA USA Department of Global Medical Affairs Wyeth Research Collegeville PA USA Department of Neuroscience Wyeth Research Paris France Department of Global Biostatistics and Programming Wyeth Research Collegeville PA USA
Objective:To assess the efficacy of desvenlafaxine succinate (DVS) treatment in patients with major depressive disorder (MDD).Methods:Seven randomized, double-blind, placebo-controlled, short-term studies were pooled ...
来源: 评论
EFFICACY AND SAFETY OF EXPERIMENTAL CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS VERSUS AXICABTAGENE CILOLEUCEL (YESCARTA) FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: MATCHING ADJUSTED INDIRECT COMPARISONS AND SYSTEMATIC REVIEW
收藏 引用
Hematology, Transfusion and Cell Therapy 2021年 43卷 S256-S256页
作者: B Weinstein B Muresan S Solano AV Macedo Y Lee Y Su Y Ahn C Camargo G Kim D Carpenter Department of Environmental Health Sciences School of Public Health University at Albany Rensselaer United Kingdom Health Sciences Unit University of Groningen University Medical Center Groningen Groningen The Netherlands Principles and Practice of Clinical Research (PPCR) Program ECPE Harvard T.H. Chan School of Public Health Boston United Kingdom Hematology Clinic Hospital da Polícia Militar Belo Horizonte MG Brazil Department of Pharmaceutical Sciences School of Pharmacy Texas Tech University Health Sciences Center Amarillo United Kingdom Inari Medical Biostatistics and Programming Department Irvine United Kingdom Department of Plastic Surgery Faculdade de Medicina Universidade de São Paulo (FMUSP) São Paulo SP Brazil Institute of Experimental and Clinical Pharmacology and Toxicology Faculty of Medicine University of Freiburg Freiburg Germany Institute for Health and the Environment University at Albany Rensselaer United Kingdom
Introduction Despite the high response rates seen with Chimeric Antigen Receptor (CAR) T-cell therapy for relapsed/refractory Large B-cell lymphoma (R/R LBCL), post-therapy relapse remains a key challenge. To date, no...
来源: 评论
713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
收藏 引用
Annals of Oncology 2023年 34卷 S493-S494页
作者: I. Dagogo-Jack A. Dowlati R. Guo M.M. Awad A. Swalduz E. Calvo V. Moreno Garcia A.A. Adjei P. Lorusso S. Punekar T.A. Leal T.A. Yap A. Italiano W. Novotny C. Tankersley S. Rowe G. Paris W. Sun A.I. Spira B. Besse Medicine Hematology/Oncology Department Massachusetts General Hospital-Surgical Oncology Division Boston MA USA Department of Hematology and Oncology University Hospitals Seidman Cancer Center and Case Western Reserve University Cleveland OH USA Gynecologic Medical Oncology Memorial Sloan Kettering Cancer Center New York NY USA Medical Oncology Dana-Farber Cancer Institute Boston MA USA Medical Oncology Centre Léon Bérard Lyon France Medical Oncology Division START Madrid-CIOCC Centro Integral Oncológico Clara Campal Madrid Spain Clinical Research Phase 1 Trials Unit START Madrid-FJD Hospital Fundación Jiménez Díaz Madrid Spain Taussig Cancer Institute Cleveland Clinic Cleveland OH USA Developmental Therapeutics Medical Oncology Yale Cancer Center New Haven CT USA Hematology and Oncology NYU Langone Health New York NY USA Hematology & Oncology Winship Cancer Institute of Emory University Atlanta GA USA Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston TX USA Early Phase Trials Unit Institut Bergonié and Faculty of Medicine University of Bordeaux Bordeaux France Clinical Development Prelude Therapeutics Inc. Wilmington DE USA Clinical Operations Prelude Therapeutics Inc. Wilmington DE USA Translation Medicine Prelude Therapeutics Wilmington DE USA Biostatistics and Programming Prelude Therapeutics Wilmington DE USA Research Institute NEXT Oncology-Virginia Fairfax VA USA Department of Oncology Medicine Gustave Roussy Villejuif France
来源: 评论
1261TiP CARMEN-GC01: Phase II, open-label, single-arm study of tusamitamab ravtansine in combination with ramucirumab in pretreated patients with gastric or gastroesophageal junction adenocarcinoma (GA/GEJA)
收藏 引用
Annals of Oncology 2022年 33卷 S1124-S1124页
作者: F.M. Esposito J. Lee S.Y. Rha K.D. Penkov A. Moisseev M. Van Den Eynde H. Prenen M. Díez García M. Gumus T. Sagawa M. Nechaeva T. Kajiwara H. Harputluoglu L. Charbonnier S. Bensfia N. Yang D-Y. Oh Medical Oncology Department/ICMHO Hospital Clínic de Barcelona Barcelona Spain Department of Hematology-Oncology Samsung Medical Center Seoul Republic of Korea Department of Medical Oncology Yonsei Cancer Center Yonsei University Health System Seoul Republic of Korea Oncology Department Euromedservice St. Petersburg Russian Federation Medical Oncology and Gastroenterology Department Medical Clinic of NACPP Moscow Russian Federation Oncology and Gastroenterology Department Cliniques Universitaires Saint-Luc Brussels Belgium Oncology Department UZA Edegem Belgium Medical Oncology Department Hospital Universitario Vall d'Hebron Barcelona Spain Medical Oncology Department Istanbul Medeniyet University Istanbul Turkey Gastroenterology Department National Hospital Organization Hokkaido Cancer Center Sapporo Hokkaido Japan Clinical Oncological Dispensary State Budgetary Healthcare Institution of Arkhangelsk Region Arkhangelsk Russian Federation Department of Gastrointestinal Medical Oncology National Hospital Organization Shikoku Cancer Center Matsuyama Ehime Japan Medical Oncology Department Inonu University Medical Faculty Inonu University Turgut Ozal Medical Center Malatya Turkey Biostatistics & Programming Sanofi Chilly-Mazarin France Clinical Development Sanofi Cambridge MA USA Clinical Development Sanofi Shanghai China Department of Internal Medicine Seoul National University Hospital Seoul Republic of Korea
来源: 评论
2376. Incidence ofClostridioides difficileInfection Among United States Medicare Advantage Enrollees
收藏 引用
Open Forum Infectious Diseases 2019年 第SUPPLEMENT_2期6卷 S819–S820页
作者: Heinrich, Kirstin Emir, Birol Ivanova, Jasmina Zhou, Jingying Yu, Holly Health Economics and Outcomes Research Pfizer Inc. Collegeville Pennsylvania Biostatistics Pfizer Inc. New York New York Real-World Data and Analytics Pfizer Inc. New York New York Statistical Programming Pfizer Inc. New York New York Outcome Research Heath Economics Pfizer Inc. Collegeville Pennsylvania
BackgroundClostridioides difficileinfection (CDI) may be life-threatening, and individuals aged ≥ 65 years are at increased risk. CDI burden among Medicare fee-for-service enrollees and nursing home residents in the ...
来源: 评论
845P Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study
收藏 引用
Annals of Oncology 2022年 33卷 S936-S936页
作者: J.M. Kirkwood Y. Zakharia D. Davar E. Buchbinder T. Medina A. Daud A. Ribas B. Chmielowski J.J. Niu G.T. Gibney K.A. Margolin A.J. Olszanski I. Mehmi T. Sato M. Shaheen L. Zhao D. Bobilev A.M. Krieg J. Wooldridge M. Milhem Division of Hematology/Oncology University of Pittsburgh Medical Center Pittsburgh PA USA Cancer Department Internal Medicine University of Iowa Iowa City IA USA Medicine-Medical Oncology Dana Farber Cancer Institute Boston MA USA Medicine-Medical Oncology University of Colorado Denver Aurora CO USA Medicine University of California San Francisco San Francisco CA USA Molecular and Medical Pharmacology University of California Los Angeles Los Angeles CA USA Hematology/Oncology University of California Los Angeles Los Angeles CA USA Hematology/Oncology Banner MD Anderson Cancer Center Gilbert AZ USA Medical Oncology Georgetown Lombardi Comprehensive Cancer Center Washington DC USA SJCI Melanoma Program City of Hope Comprehensive Cancer Center Santa Monica CA USA Hematology/Oncology Fox Chase Cancer Center Philadelphia PA USA Hematology/Oncology The Angeles Clinic and Research Institute Los Angeles CA USA Medical Oncology Thomas Jefferson University Philadelphia PA USA Oncology University of Arizona Tucson AZ USA Biostatistics & Programming Checkmate Pharmaceuticals Inc. Cambridge MA USA Clinical Development Checkmate Pharmaceuticals Inc. Cambridge MA USA Scientific Affairs Checkmate Pharmaceuticals Inc. Cambridge MA USA Medical Affairs Checkmate Pharmaceuticals Inc. Cambridge MA USA Internal Medicine University of Iowa Iowa City IA USA
来源: 评论